Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Organisation › Details

Rigontec GmbH

Rigontec is the leader in RIG-I targeting therapeutics. Utilizing the proprietary RIG-I agonist approach, the company harnesses one of the most essential pathways in the innate immune system to pioneer a novel immuno-oncology treatment approach. Rigontec’s proprietary agonists specifically activate RIG-I, inducing both immediate and long-term anti-tumor immunity and have proven substantial local and systemic tumor regression in several relevant in vivo models. In addition to malignant diseases, proprietary RNA molecules can be developed for the treatment of infectious and inflammatory diseases. Rigontec was founded in 2014 as a spin-out of the University Bonn, Germany, and has to date raised close to €30 million from experienced life science investors including Boehringer Ingelheim Venture Fund, Forbion Capital Partners, High-Tech Gru¨nderfonds, MP Healthcare Venture Management, NRW.BANK, Sunstone Capital and Wellington Partners Life Sciences. *


Period Start 2014-01-01 splitoff
  Group Merck (US) (MSD) (Group)
  Predecessor University of Bonn (Rheinsche Friedrich-Wilhelms-Universität Bonn)
Products Industry RNA-based therapeutic
  Industry 2 ImO1100 (Rigontec)
Persons Person Schetter, Christian (Arix Bioscience 201812– Entrepreneur In Residence before Rigontec + Fresenius Biotech + Coley GmbH)
  Person 2 de Baey-Diepolder, Annegret (Rigontec 201410 Managing Director before GIMV + TVM Capital + Micromet)
Region Region Martinsried
  Country Germany
  Street 19 Am Klopferspitz
  City 82152 Martinsried
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: Merck & Co., Inc.. (9/6/17). "Press Release: Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology". Kenilworth, NJ & Munich.
Record changed: 2018-12-17


Picture [iito] Plain Stupid Simple 650x80px

More documents for Merck (US) (MSD) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC B Preview Download 650x300px

» top